Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous BCAA for Overt Hepatic Encephalopathy in ACLF
NCT05700695Phase 1Completed
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Jan 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Branchamin in hepatic encephalopathy (HE) (2 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoint: Overall Survival at Day 28. Started Jan 2023; status: completed.
02
Drugs
Branchamin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT05700695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05700695.